Expression Value of Rab10 in Breast Cancer
Clinical and Experimental Obstetrics & Gynecology, 2023 Background: Rab10 is a small GTPase protein belonging to the Ras superfamily. It is expressed and plays a role in a variety of malignant tumours. However, the expression of Rab10 and its role in breast cancer (BC) prognosis remains unclear.
Jian Zhuo +9 more
doaj +1 more source
Smoking history and breast cancer risk by pathological subtype: MCC-Spain study
Tobacco Induced Diseases, 2023 Introduction The role of cigarette smoking on breast cancer risk remains controversial, due to its dual carcinogenic-antiestrogenic action. Methods In the population-based multi-case-control study (MCC-Spain), we collected epidemiological and clinical ...
Belén Peñalver-Argüeso +22 more
doaj +1 more source
Acta Dermato-Venereologica, 2023 is missing (Short communication)
Yui Hirano-Lotman +4 more
doaj +1 more source
Pattern of HER2 Overexpression in Urinary Bladder Carcinomas in Kano, Nigeria
The Annals of African Surgery, 2023 Background: The worldwide distribution of bladder cancer varies, conforming to differences in environmental and genetic risk factors. HER2 neu is overexpressed in many human cancers, including urinary bladder carcinomas.
Muhammad Sanusi Haruna +2 more
doaj +1 more source
South Asian Journal of Cancer, 2022 Biren Parikh Introduction Hormonal status and HER2 expression are valuable biomarkers and dictate the management of the patients diagnosed with invasive breast cancer (IBC).
B. R. Nagarjun +4 more
doaj +1 more source
Molecular Cloning of DARPins G3 in pET28b Expression Vector and Optimization of the Expression of This Protein in Escherichia Coli [PDF]
Research in Molecular Medicine, 2022 Background: Human epidermal growth factor receptor 2 (HER2) is over-expressed in breast, ovarian, gastric, and prostate cancers and is used as a tumor marker in the diagnosis of cancer. Monoclonal antibodies have been used as a diagnostic and therapeutic
Nadereh Bakhshandeh +4 more
doaj
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. [PDF]
, 2014 IntroductionThe purpose of this study was to retrospectively explore the relationship between human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) expression and efficacy in patients receiving trastuzumab plus docetaxel (HT) or ...
Amler, Lukas C +6 more
core +9 more sources
Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells [PDF]
, 2013 Breast cancer is the most common female cancerous disease and the second most cause of cancer death in women. About 20-30% of these tumors exhibit an amplification of the HER2/ErbB2 receptor, which is coupled to a more aggressive and invasive growth of ...
Brobeil, Alexander +4 more
core +5 more sources
Assessment of correlation between Trastuzumab resistance and miR-885-3p relative expression in the BT-474 Human Breast Cancer Cell Line [PDF]
Journal of Epigenetics, 2019 Trastuzumab has been applied widely in the treatment of breast cancer. The majority of initial responders display disease progression again within one year.
Zohreh Rezaei, Kazem Dastjerdi
doaj +1 more source
Anti‐proliferative effects of pentagamaboronon‐0‐sorbitol on HER2‐overexpressing breast cancer cells
Indonesian Journal of Biotechnology, 2022 HER2‐positive breast cancer is an aggressive form of the disease that is associated with poor prognosis and chemo‐resistance. As such, investigation continues into the development of a new HER2‐targeted drug for breast cancer. This study investigated the
Lailatul Qodria +3 more
doaj +1 more source